1. Starting treatment with nivolumab/ipilimumab rather than dabrafenib/trametinib resulted in an improvement in 2-year overall survival (72% vs 52%) 2. ...
1. In the toripalimab arm, progression-free survival was longer, overall survival at the second interim analysis was longer, and objective ...
Click to read this study in The Lancet Oncology.
Click to read this study in the European Journal of Cancer.
Click to read this study in JAMA Network Open.
1. This is the first human clinical trial of evorpacept, a CD47 inhibitor, and the results suggest an acceptable safety ...
1. Receiving at least 20% of infusions after 1630h was associated with decreased overall survival in patients treated with immune-checkpoint ...
Click to read the study in the European Journal of Cancer.
Click to read the study in the European Journal of Cancer.
